Indianapolis and San Diego (ots/PRNewswire) - - Trial to Study Use of Biomarker to Better Define Xigris Patients and Treatment Response Eli Lilly and Company (NYSE: LLY) and Biosite(R) Incorporated (Nasdaq: BSTE) today announced the two companies have signed an agreement to collaborate in connection with a clinical trial employing a tailored therapy ...
Indianapolis (ots/PRNewswire) - - Enzastaurin Study Enrolling Patients with Glioblastoma One of the deadliest and rarest forms of cancer is the focus of a Phase III study initiated by Eli Lilly and Company today. Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form ...
Indianapolis, and Ingelheim, Germany (ots/PRNewswire) - - Eli Lilly and Company and Boehringer Ingelheim Announce Changes to Their Contractual Agreements for Yentreve(R)/AriClaim(R) Eli Lilly and Company and Boehringer Ingelheim announced today that the alliance will change the nature of its ...
Indianapolis (ots/PRNewswire) - Data presented today offer evidence that an investigational targeted therapy may be useful in treating patients with the most common form of non-Hodgkin's lymphoma (NHL). The five-year survival rate of U.S. patients with NHL is only 59 percent with standard therapies, according to the Lymphoma Research Foundation. Diffuse large ...
Indianapolis and Ingelheim, Germany (ots/PRNewswire) - Your mother, your friend, your sister - chances are one of these three women have suffered from the symptoms of stress urinary incontinence (SUI), but she has been too embarrassed to admit it. This is just one of the staggering facts revealed by a ...
Athens, Greece (ots/PRNewswire) - - 80 percent of diabetes patients in study preferred inhaled insulin system to mealtime injections Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today presented detailed results from a Phase 2 clinical study of inhaled insulin in people with type 1 ...
Athens, Greece (ots/PRNewswire) - - Approximately 40 percent of people with diabetes develop nephropathy, the leading cause of kidney failure Eli Lilly and Company (NYSE: LLY) today announced encouraging results from a one-year pilot study examining the effect of ruboxistaurin mesylate in persons with ...
Athens, Greece (ots/PRNewswire) - -- Patients on exenatide also lost weight, while glargine patients gained weight -- Eli Lilly and Company (NYSE: LLY) and Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) today announced results from a study indicating that exenatide improves blood sugar levels as effectively as ...
Athens, Greece (ots/PRNewswire) - - Improvements in cardiovascular risk factors were also observed Eli Lilly and Company (NYSE: LLY) and Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) today presented results from a study indicating that the investigational compound exenatide showed sustained improvements in ...
Indianapolis (ots/PRNewswire) - - Europe's only approved non-stimulant ADHD medication offers a new treatment choice Eli Lilly and Company's Strattera(R), the only approved non-stimulant medication proven clinically effective(1) at treating the potentially serious symptoms of ...
Orlando, Florida (ots/PRNewswire) - Viktoria Kun, Health Correspondent on the Hungarian national daily newspaper Népszabadság, and Ioanna Soufleri, Science Editor on the Greek national daily newspaper To Vima, have been named today by The European School of Oncology (ESO) as joint winners of the ACE (Awarding ...
Indianapolis and Tokyo (ots/PRNewswire) - In three early-phase trials,(1,2,3) an investigational platelet inhibitor, prasugrel (CS-747, LY640315), demonstrated significantly higher and more consistent inhibition of platelet aggregation (IPA) compared to both placebo and the current standard of care, clopidogrel ...
Indianapolis, November 1 (ots/PRNewswire) - New data presented today confirm that advanced lung cancer patients can look forward to better-quality survival when treated with Alimta(R) (pemetrexed), a newly approved anticancer agent in the European Union compared with Taxotere(R) (docetaxel). Eli Lilly and Company ...
Indianapolis (ots/PRNewswire) - - New Analysis Showed Teriparatide Prevented Fracture Risk Associated with Increasing Number, Severity of Osteoporotic Fractures Data presented at the American Society for Bone and Mineral Research (ASBMR) 26th annual meeting in Seattle, Wash., showed that the number and severity of prior fractures are strong predictors of future fractures in postmenopausal women with ...
Indianapolis (ots/PRNewswire) - Data presented at the 26th annual meeting of the American Society for Bone and Mineral Research (ASBMR), Seattle, Wash., shows that the ability of teriparatide to prevent fractures remained consistent regardless of pretreatment bone turnover status.(1) Bone is living tissue that constantly regenerates itself by breaking down and ...
Indianapolis (ots/PRNewswire) - Eli Lilly and Company's Gemzar(R) (gemcitabine), approved to treat patients with pancreas, non-small-cell lung, metastatic breast and bladder cancers, receives approvals for a fifth indication. Lilly announced today that regulatory officials in several European markets ...